|Day Low/High||133.83 / 136.86|
|52 Wk Low/High||55.00 / 133.62|
- Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo
Jim Cramer is bullish on Domino's Pizza, Xylem, and Incyte, but he's waiting for better pricing for NXP Semiconductor.
Jim Cramer says the markets could be further rattled by the Federal Reserve meeting.
Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday,...
Credit Suisse analyst Alethia Young isn't worried about Incyte.
Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed...
Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's investigational...
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...
Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...
Incyte and Merck are combining two cancer immunotherapy drugs to treat patients with non-small cell lung cancer.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARR, AYA, CMCT, CRMT, INCY, NMR Downgrades: ASC, CPLP, FITB, MTRX, PAM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017...
Jim Cramer makes the calls on Tanger Factory Outlet Centers, Gilead Sciences, and Qorvo in the 'Mad Money' Lightning Round.
Ahead of Fed's June meeting, investors will need to start paying close attention to Fed officials and economic data.
Jim Cramer is bullish on Walgreens Boots Alliance, Becton Dickinson, and General Mills.
Money managers are piling back into growth stocks without hesitation, says Jim Cramer.
Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.
Stocks add to gains on Thursday, coming back from their worst losses in eight months a day earlier, as a positive quarter for Walmart boosts consumer names.
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
Stocks turn higher as Walmart does the heavy lifting on the Dow and S&P 500, and health care gives a boost to the Nasdaq.
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
Incyte Corporation (Nasdaq:INCY) today announced that the American Society of Clinical Oncology (ASCO) has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's...
Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte's selective IDO1 enzyme inhibitor, in combination with Keytruda ®...
Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.